• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,026.17
  • -0.85 %
  • -$326.17
  • FTSE
  • $8,149.27
  • 0.79 %
  • $64.20
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Price, News & Analysis

Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Price, News & Analysis

Currency in USD Disclaimer

$18.27

-$0.44

(-2.35%)

Day's range
$18.21
Day's range
$18.83
50-day range
$17.05
Day's range
$22.51
  • Country: US
  • ISIN: US04280A1007
52 wk range
$17.05
Day's range
$39.83
  • CEO: Dr. Christopher R. Anzalone Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -1.20
  • Piotroski Score 1.00
  • Grade Buy
  • Symbol (ARWR)
  • Company Arrowhead Pharmaceuticals, Inc.
  • Price $18.27
  • Changes Percentage (-2.35%)
  • Change -$0.44
  • Day Low $18.21
  • Day High $18.83
  • Year High $39.83

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/26/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $43.50
  • High Stock Price Target $75.00
  • Low Stock Price Target $27.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$4.23
  • Trailing P/E Ratio -5.65
  • Forward P/E Ratio -5.65
  • P/E Growth -5.65
  • Net Income $-205,275,000

Income Statement

Quarterly

Annual

Latest News of ARWR

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Arrowhead Pharmaceuticals, Inc. Frequently Asked Questions

  • What is the Arrowhead Pharmaceuticals, Inc. stock price today?

    Today's price of Arrowhead Pharmaceuticals, Inc. is $18.27 — it has decreased by -2.35% in the past 24 hours. Watch Arrowhead Pharmaceuticals, Inc. stock price performance more closely on the chart.

  • Does Arrowhead Pharmaceuticals, Inc. release reports?

    Yes, you can track Arrowhead Pharmaceuticals, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Arrowhead Pharmaceuticals, Inc. stock forecast?

    Watch the Arrowhead Pharmaceuticals, Inc. chart and read a more detailed Arrowhead Pharmaceuticals, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Arrowhead Pharmaceuticals, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Arrowhead Pharmaceuticals, Inc. stock ticker.

  • How to buy Arrowhead Pharmaceuticals, Inc. stocks?

    Like other stocks, ARWR shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Arrowhead Pharmaceuticals, Inc.'s EBITDA?

    Arrowhead Pharmaceuticals, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Arrowhead Pharmaceuticals, Inc.’s financial statements.

  • What is the Arrowhead Pharmaceuticals, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -0.8527011029, which equates to approximately -85.27%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Arrowhead Pharmaceuticals, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Arrowhead Pharmaceuticals, Inc.'s financials relevant news, and technical analysis. Arrowhead Pharmaceuticals, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Arrowhead Pharmaceuticals, Inc. stock currently indicates a “sell” signal. For more insights, review Arrowhead Pharmaceuticals, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.